Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


KV Acquires Particle and Coating Technologies

This article was originally published in The Pink Sheet Daily

Executive Summary

PCT’s Proprietary coating technologies will augment KV’s development of both generics and branded products, firm says.

You may also be interested in...

KV Gets ANDA Approval For Two Strengths Of AstraZeneca’s Toprol-XL

KV believes it has 180-day exclusivity for the 100 mg and 200 mg strengths of the hypertension treatment.

Vivus Sells EvaMist Rights To KV For $150 Million

Vivus CEO tells “The Pink Sheet” DAILY that sale of estrogen product will allow firm to focus on obesity candidate Qnexa.

Solvay's Androgel REMS Proposal May Need More Restrictions - Cmte.

Solvay may need a more restrictive Risk Evaluation and Mitigation Strategy for AndroGel 1% to adequately warn against the danger of secondary transfer of the testosterone gel, according to some members of FDA's Pediatric Advisory Committee





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts